Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
Shampa Das, Jianguo Li, Jon Armstrong, Maria Learoyd, Timi Edeki, Shampa Das, Jianguo Li, Jon Armstrong, Maria Learoyd, Timi Edeki
Abstract
We assessed pharmacokinetic and safety profiles of ceftazidime-avibactam administered ± metronidazole, and whether drug-drug interactions exist between ceftazidime and avibactam, or ceftazidime-avibactam and metronidazole. The first study (NCT01430910) involved two cohorts of healthy subjects. Cohort 1 received ceftazidime-avibactam (2000-500 mg) as a single infusion or as multiple intravenous infusions over 11 days to evaluate ceftazidime-avibactam pharmacokinetics. Cohort 2 received ceftazidime, avibactam, or ceftazidime-avibactam over 4 days to assess drug-drug interaction between ceftazidime and avibactam. The second study (NCT01534247) assessed interaction between ceftazidime-avibactam and metronidazole in subjects receiving ceftazidime-avibactam (2000-500 mg), metronidazole (500 mg), or metronidazole followed by ceftazidime-avibactam over 4 days. In all studies, subjects received a single-dose on the first and final days, and multiple-doses every 8 h on intervening days. Concentration-time profiles for ceftazidime and avibactam administered as single- or multiple-doses separately or together with/without metronidazole were similar. There was no evidence of time-dependent pharmacokinetics or accumulation. In both interaction studies, 90% confidence intervals for geometric least squares mean ratios of area under the curve and maximum plasma concentrations for each drug were within the predefined interval (80-125%) indicating no drug-drug interaction between ceftazidime and avibactam, or ceftazidime-avibactam and metronidazole. There were no safety concerns. In conclusion, pharmacokinetic parameters and safety of ceftazidime, avibactam, and metronidazole were similar after single and multiple doses with no observed drug-drug interaction between ceftazidime and avibactam, or ceftazidime-avibactam and metronidazole.
Keywords: Avibactam; ceftazidime; drug–drug interaction; infectious disease; pharmacokinetics.
Figures
References
- Berkhout J, Melchers MJ, Seyedmousavi S, Lagarde CM, Schuck V, Nichols WW, et al. (2013). ( Exposure response relationships of ceftazidime and avibactam in a neutropenic thigh model. 53rd Intersceince Conference on Antimicrobial Agents and Chemotherapy, 2013, Denver, CO, USA.
- Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN. 10 x ‘20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685–1694. , et al. (
- Das S, Armstrong J, Mathews D, Li J, Edeki T. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime–avibactam or ceftaroline fosamil-avibactam. J Clin Pharmacol. 2014;54:331–340.
- Food and Drug Administration. 2012. Guidance for industry: Drug Interaction Studies - study design, data analysis, implications for dosing, and labeling recommendations. Available at . (accessed 12 June 2015)
- Food and Drug Administration. 2015. AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use: highlights of prescribing information. Available at . (accessed 12 June 2015)
- GlaxoSmithKline (2013). Fortum®1 g injection SPC. Available at . (accessed 12 February 2014)
- Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119–1125.
- Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum ß-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86:250–259.
- Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother. 2011;55:2434–2437. , et al. (
- Li J, Zhou D, Al Huniti N, Bouchillon S, Bradford P, Nichols WW. (2014). , et al. ( Pharmacokinetic/Pharmacodynamic target attainment (PTA) and cumulative fractions of response (CFR) for ceftazidime, ceftazidime–avibactam, and meropenem against bacteria isolated from patients in Europe in 2012. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2014, Barcelona, Spain
- Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390–394. , et al. (
- Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68:1183–1192.
- Mazuski JE, Gasink L, Armstong J, Broadhurst H, Stone G, Rank D. et al. (2015). , Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a Phase III programme. 25th European Congress of Clinical Microbiology and Infectious Diseases, 2015, Copenhagen, Denmark
- Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35:307–317.
- Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68:900–906.
- Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362:1804–1813.
- Sillén H, Mitchell R, Sleigh R, Mainwaring G, Catton K, Houghton R. Determination of avibactam and ceftazidime in human samples by liquid chromatography and mass spectrometry. Bioanalysis. 2015;7:1423–1434. , et al. (
- Sommers DK, Walters L, Van WM, Harding SM, Paton AM, Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23:892–896.
- Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64:326–329. , et al. (
- Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015;37:877–886.
- Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J. Efficacy and safety of ceftazidime–avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–1931. , et al. (
- Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug–drug interaction potential. Drug Metab Dispos. 2014;42:932–942. , et al. (
- Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984;25:201–204.
- Winthrop Pharmaceuticals UK Limited (2013). Flagyl®400 mg tablets SPC. Available at . (accessed 12 February 2014)
Source: PubMed